Drug Carrier-Oriented Polygeline for Preparing Novel Polygeline-Bound Paclitaxel Nanoparticles

Du, 2017, Preparation of graphene-copper nanocomposite for constructing electrochemical sensor for paclitaxel anti-cancer drug detection in Taxus Chinensis, Int J Electrochem Sci, 12, 2563, 10.20964/2017.03.77 Hwu, 2009, Targeted paclitaxel by conjugation to iron oxide and gold nanoparticles, J Am Chem Soc, 131, 66, 10.1021/ja804947u Liu, 2011, Enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel, Int J Mol Sci, 12, 4395, 10.3390/ijms12074395 Jin, 2016, Core-shell nanocarriers with high paclitaxel loading for passive and active targeting, Sci Rep, 6, 27559, 10.1038/srep27559 Gradishar, 2006, Albumin-bound paclitaxel: a next-generation taxane, Expert Opin Pharmacother, 7, 1041, 10.1517/14656566.7.8.1041 Singla, 2002, Paclitaxel and its formulations, Int J Pharm, 235, 179, 10.1016/S0378-5173(01)00986-3 Zhang, 2009, A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors, Biomed Pharmacother, 63, 603, 10.1016/j.biopha.2008.10.001 Lo, 2010, Self-emulsifying O/W formulations of paclitaxel prepared from mixed nonionic surfactants, J Pharm Sci, 99, 2320, 10.1002/jps.21993 Ryu, 2008, Synthesis and anti-cancer efficacy of rapid hydrolysed water-soluble paclitaxel pro-drugs, J Biomater Sci Polym Ed, 19, 311, 10.1163/156856208783720994 Shanmugam, 2011, Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts, Int J Pharm, 403, 130, 10.1016/j.ijpharm.2010.10.033 Zhang, 2011, A hydrotropic β-cyclodextrin grafted hyperbranched polyglycerol co-polymer for hydrophobic drug delivery, Acta Biomater, 7, 585, 10.1016/j.actbio.2010.08.029 Cai, 2014, Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2, Phytomedicine, 21, 984, 10.1016/j.phymed.2014.02.012 Gelderblom, 2001, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, Eur J Cancer, 37, 1590, 10.1016/S0959-8049(01)00171-X ten Tije, 2003, Pharmacological effects of formulation vehicles : implications for cancer chemotherapy, Clin Pharmacokinet, 42, 665, 10.2165/00003088-200342070-00005 John, 2003, Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer, Am J Physiol Lung Cell Mol Physiol, 284, L187, 10.1152/ajplung.00152.2002 Neesse, 2014, SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice, Gut, 63, 974, 10.1136/gutjnl-2013-305559 Wang, 2014, Preparation, pharmacokinetics, biodistribution, antitumor efficacy and safety of Lx2-32c-containing liposome, PLoS One, 9, e114688, 10.1371/journal.pone.0114688 Kim, 2007, Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer, Ann Oncol, 18, 2009, 10.1093/annonc/mdm374 Kim, 2004, Phase I and pharmacokinetic study of genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies, Clin Cancer Res, 10, 3708, 10.1158/1078-0432.CCR-03-0655 Slingerland, 2013, Bioequivalence of liposome-entrapped paclitaxel easy-to-use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer, Clin Ther, 35, 1946, 10.1016/j.clinthera.2013.10.009 Kato, 2012, Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer, Invest New Drugs, 30, 1621, 10.1007/s10637-011-9709-2 Awada, 2014, A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC), Ann Oncol, 25, 824, 10.1093/annonc/mdu025 Shin, 2009, Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form, Cancer Chemother Pharmacol, 64, 87, 10.1007/s00280-008-0849-9 Desai, 2006, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel, Clin Cancer Res, 12, 1317, 10.1158/1078-0432.CCR-05-1634 Kundranda, 2015, Albumin-bound paclitaxel in solid tumors: clinical development and future directions, Drug Des Devel Ther, 9, 3767, 10.2147/DDDT.S88023 Katharine, 2001, Massive blood transfusion, Indian J Pediatr, 68, 145, 10.1007/BF02722034 Olender, 1971, Application of haemaccel in the extracorporeal circulation during heart surgery, Pol Med J, 10, 909 Oosterhuis, 1966, Polygeline as a vitreous substitute: Ii. clinical results, Arch Ophthalmol, 76, 374, 10.1001/archopht.1966.03850010376014 Schwenke, 1978, The science and technology of gelatin. Herausgegeben von AG. Ward UA. Courts, XVI und 564 Seiten mit zahlreichen Abb. u. Tab., Academic Press London, New York, San Francisco 1977. Preis: 18,00 £; 39,50 $, Food Nahrung, 22, 444, 10.1002/food.19780220424 Du, 2014, Drug carriers for the delivery of therapeutic peptides, Biomacromolecules, 15, 1097, 10.1021/bm500169p Gómez-Guillén, 2011, Functional and bioactive properties of collagen and gelatin from alternative sources: a review, Food Hydrocoll, 25, 1813, 10.1016/j.foodhyd.2011.02.007 Kołodziejska, 2008, Effect of extracting time and temperature on yield of gelatin from different fish offal, Food Chem, 107, 700, 10.1016/j.foodchem.2007.08.071 Saddler, 1987, The new generation gelatins. A review of their history, manufacture and properties, Anaesthesia, 42, 998, 10.1111/j.1365-2044.1987.tb05376.x Merikallio, 1976, Haemodilution in cardiopulmonary bypass using a gelatine derivative for priming, Ann Chir Gynaecol, 65, 138 Johnston-Banks, 1990, Gelatine, 233 Newman, 2012, Assessing the performance of amorphous solid dispersions, J Pharm Sci, 101, 1355, 10.1002/jps.23031 Desai NP, Tao C, Yang A, et al. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof. Patent No.: US 6749868 B1, Date of Patent June 15, 2004. McCahon, 2010, Pharmacology of plasma expanders, Anaesth Intensive Care Med, 11, 75, 10.1016/j.mpaic.2009.10.009